Mogy Joel R Investment Counsel Inc. Purchases 7,733 Shares of Eli Lilly and Company (NYSE:LLY)

Mogy Joel R Investment Counsel Inc. increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 39.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 27,177 shares of the company’s stock after buying an additional 7,733 shares during the period. Eli Lilly and Company accounts for 1.2% of Mogy Joel R Investment Counsel Inc.’s holdings, making the stock its 26th biggest holding. Mogy Joel R Investment Counsel Inc.’s holdings in Eli Lilly and Company were worth $15,842,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of LLY. Warren Street Wealth Advisors LLC increased its stake in Eli Lilly and Company by 18.9% in the third quarter. Warren Street Wealth Advisors LLC now owns 835 shares of the company’s stock valued at $449,000 after purchasing an additional 133 shares in the last quarter. Olistico Wealth LLC boosted its holdings in Eli Lilly and Company by 2.7% during the third quarter. Olistico Wealth LLC now owns 2,447 shares of the company’s stock worth $1,314,000 after purchasing an additional 65 shares during the last quarter. Gemmer Asset Management LLC boosted its holdings in Eli Lilly and Company by 78.0% during the third quarter. Gemmer Asset Management LLC now owns 1,340 shares of the company’s stock worth $720,000 after purchasing an additional 587 shares during the last quarter. Blue Fin Capital Inc. boosted its holdings in Eli Lilly and Company by 0.9% during the third quarter. Blue Fin Capital Inc. now owns 9,901 shares of the company’s stock worth $5,318,000 after purchasing an additional 86 shares during the last quarter. Finally, Aaron Wealth Advisors LLC boosted its stake in Eli Lilly and Company by 12.9% in the third quarter. Aaron Wealth Advisors LLC now owns 6,012 shares of the company’s stock valued at $3,229,000 after acquiring an additional 685 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on LLY shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research note on Monday, April 15th. Truist Financial reissued a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 22nd. BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a research report on Wednesday, February 21st. Finally, Barclays boosted their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Trading Up 1.2 %

Shares of Eli Lilly and Company stock traded up $8.64 during trading on Friday, reaching $733.51. The company’s stock had a trading volume of 2,009,249 shares, compared to its average volume of 2,265,427. Eli Lilly and Company has a 52-week low of $380.77 and a 52-week high of $800.78. The company has a market cap of $696.95 billion, a price-to-earnings ratio of 126.47, a PEG ratio of 1.58 and a beta of 0.34. The firm’s 50-day moving average is $761.79 and its two-hundred day moving average is $666.06. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter in the prior year, the company earned $2.09 EPS. The firm’s revenue was up 28.1% on a year-over-year basis. On average, sell-side analysts anticipate that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.